Bruce Goldman, Stanford Medicine, April 10, 2024 The lung-cell type that’s most susceptible to infection by SARS-CoV-2, the virus that causes COVID-19, is not the one previously assumed to be most vulnerable. What’s more, the virus enters this susceptible cell via …
Ivermectin and COVID-19
FDA, April 5, 2024 One of the U.S. Food and Drug Administration’s jobs is to carefully evaluate the scientific data on a drug to be sure that it is both safe and effective for a particular use. There continues to …
How bad are flu, COVID-19 and RSV? These charts show how respiratory viruses are spreading in the US
By Nicky Forster, AP News, April 5, 2024 The 2023-24 respiratory virus season is ebbing as viral activity from flu, COVID-19 and RSV falls across most of the U.S. Here’s the situation in four charts: How active are the respiratory …
FDA authorizes COVID drug Pemgarda for high-risk patients
By Carrie Macmillian, Yale Medicine, April 5, 2024 The Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to a medicine meant to protect certain immunocompromised people against COVID-19. The medicine, pemivibart (brand name Pemgarda™), is for people …
No increased stroke risk after COVID-19 bivalent vaccine
Batya Swift Yasgur, Medscape, March 28, 2024 Receipt of the bivalent COVID-19 vaccine was not associated with an increased stroke risk in the first 6 weeks after vaccination with either the Pfizer or Moderna vaccines, a new study of Medicare …